Sera Prognostics - Class A opened higher at $1.97, compared with its previous close of $1.94. In the last trading session, the stock traded between $1.92 and $2.06. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sera Prognostics - Class A is now worth
$ 17.88
Resulting in a loss of
$ 82.12 (82.12%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.02 (+0.93%)
Day High
$2.06
Day Low
$1.92
Day Open
$1.97
Prev Close
$1.94
Volume
17,448
1W Return
-2.83%
1M Return
-4.30%
3M Return
-1.36%
6M Return
13.18%
1Y Return
-27.21%
Fundamentals
Market Cap ($ Mn)
76
PE Ratio
-
PB Ratio
1.37
PEG Ratio
-
ROE
-41.10%
ROCE
-46.00%
EPS (TTM)
$-0.20
Investment Returns
1 Week
-2.83%
1 Month
-4.30%
3 Months
-1.36%
6 Months
13.18%
9 Months
-24.40%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
5Nov
Sera Prognostics Q3FY26 Results: Loss widens to $0.16, test volumes rise 5x
Loss per share widened to $0.16, missing analyst estimates by 14.29%. Quarterly revenue of $42,000 missed consensus estimates by 42.07%. Test volumes increased approximately fivefold compared to Q1 FY26. Medicaid coverage secured in Florida and Illinois covers 7 million lives. Operating expenses declined 11% sequentially despite commercial expansion.
8 days ago
20Aug
Sera Prognostics appoints Scott Gleason as CFO effective August 31
Sera Prognostics appoints Scott Gleason as CFO effective August 31, 2026, leveraging his 25+ years in healthcare and capital markets. Austin Aerts transitions to an advisory role. The move aims to support commercialization of the PreTRM Test.
2mo ago
13Aug
Sera Prognostics Q2 2026 loss widens to $9.1 million; Illinois Medicaid mandate
Sera Prognostics reported a Q2 2026 net loss of $9.1 million on revenue of $30,000, which grew 76% YoY but missed estimates. Operating expenses rose to $10.0 million due to commercial investments. Key positives include an Illinois Medicaid coverage mandate for its PreTRM test and expanded payer partnerships.
3mo ago
10Jul
PreTRM Test reduces NICU admissions by 22% in first-time pregnancies
Sera Prognostics Inc. announced that a new subgroup analysis from the PRIME trial showed PreTRM Test-guided care reduced NICU admissions by 22% in first-time pregnancies. Published in The Journal of Maternal-Fetal & Neonatal Medicine, the study highlights the test's ability to improve outcomes and cut costs in a population where traditional risk assessment is limited.
4mo ago
25Jun
Sera Prognostics joins $10.4M ARPA-H research program
Sera Prognostics Inc. will participate in a multi-institutional research program awarded up to $10.4 million by ARPA-H to develop a point-of-care diagnostic test for labor and delivery safety. The program aims to enhance maternal and neonatal health outcomes through innovative biomarker solutions.
